Physician profile
James Y Lim
NPI 1326167883
$210,414.43
in general payments reported to CMS, 2019-2025
42 companies · $115K in 2025
The $115K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $7,256 · 2021: $2,835 · 2022: $495 · 2023: $537 · 2024: $73K · 2025: $115K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $145K · Travel and Lodging: $37K · Food and Beverage: $6,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $144,600.00 |
| Travel and Lodging | $37,472.79 |
| Food and Beverage | $6,104.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $186,799.06 | 2024-2025 | Brixadi |
| Indivior INC. | $19,376.32 | 2019-2025 | Sublocade |
| Abbvie INC. | $886.08 | 2019-2025 | |
| Pear Therapeutics (US), INC. | $647.61 | 2021 | |
| Novo Nordisk INC | $615.19 | 2019-2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $194.67 | 2019-2025 | Trintellix |
| Biohaven Pharmaceutical Holding Company Ltd. | $181.24 | 2022 | |
| Pfizer INC. | $162.41 | 2019-2024 | |
| Glaxosmithkline, LLC. | $157.85 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $125.22 | 2019-2021 | |
| Orexo US, INC. | $100.56 | 2021-2023 | Zubsolv |
| Lilly USA, LLC | $96.01 | 2019-2024 | Mounjaro |
| Amgen INC. | $93.79 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $89.64 | 2020-2025 | Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $84.66 | 2019-2023 | Steglatro, Belsomra |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.